This compound is primarily used in the field of cancer research and therapy. It functions as a Proteolysis Targeting Chimera (PROTAC) designed to target and degrade Bcl-2, a protein that plays a critical role in preventing apoptosis in cancer cells. By degrading Bcl-2, it promotes programmed cell death in malignant cells, making it a promising tool for developing treatments for Bcl-2-dependent cancers such as certain types of leukemia and lymphoma. Its application is particularly significant in overcoming resistance to traditional Bcl-2 inhibitors, offering a novel approach to cancer therapy. Research is ongoing to evaluate its efficacy, specificity, and potential for clinical use.